TG Therapeutics (TGTX) Osake Kurssi
TG Therapeutics Kurssi
Liikevaihto on kasvanut 122,3 % vuodessa viimeisten 13 vuoden aikana 616,29 M USD:een. Osakekohtainen tulos on laskenut 10,1 % vuodessa viimeisten 15 vuoden aikana. TG Therapeuticsn nettomarginaali on nyt 72,6 %, noussut −5 204,1 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 80,50 USD, eli yli nykyhintaa 32,5 %. 14 analyytikosta 12 suosittaa ostoa — kokonaiskonsensus on Osta.
TG Therapeutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
TG Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset TG Therapeutics -osakkeesta
The business model of TG Therapeutics Inc revolves around the development and commercialization of innovative biopharmaceutical products. Specializing in the field of oncology and B-cell malignancies, TG Therapeutics focuses on creating novel therapies to address the unmet medical needs of patients. By harnessing its expertise in research and development, the company aims to discover and develop targeted therapies that can improve the outcome and quality of life for individuals battling certain types of cancer. Through strategic partnerships, clinical trials, and regulatory initiatives, TG Therapeutics Inc strives to bring next-generation treatments to market, ultimately benefiting both patients and shareholders.
TG Therapeutics Inc is primarily active in the biotechnology and healthcare industries.
The main competitors of TG Therapeutics Inc in the market include pharmaceutical companies such as AbbVie Inc., Roche Holding AG, and Johnson & Johnson. These companies operate in similar therapeutic areas and have a strong presence in the market. TG Therapeutics Inc faces competition in the development and commercialization of therapies for various conditions, such as lymphoma and chronic lymphocytic leukemia.
TG Therapeutics Inc is a renowned biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases. Established in 1993, TG Therapeutics has emerged as a key player in the pharmaceutical industry, committed to advancing medical breakthroughs. With a focus on developing targeted therapies, the company has achieved significant milestones in its history. Over the years, TG Therapeutics has successfully introduced novel drugs and treatment options, catering to unmet medical needs. Their dedication to research and development, coupled with a strong commitment to patient care, has positioned TG Therapeutics Inc as a leading name in the healthcare sector.
TG Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. Most notably, the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative therapy, umbralisib, in combination with ublituximab, for the treatment of adult patients with marginal zone lymphoma (MZL) and follicular lymphoma (FL). This approval marks a major breakthrough in the field of oncology and reinforces TG Therapeutics Inc's commitment to developing effective treatments for hematologic malignancies. Additionally, the company has successfully completed various clinical trials, demonstrating the potential of its pipeline to address unmet medical needs.
TG Therapeutics Inc is primarily present in the United States. The company's headquarters are located in New York, and it focuses on the development and commercialization of novel treatments for various B-cell malignancies and autoimmune diseases. TG Therapeutics Inc primarily operates in the United States market, fostering collaborations with healthcare providers, research organizations, and regulatory authorities to advance its innovative therapies. With an unwavering commitment to improving patient outcomes, TG Therapeutics Inc continues to drive its presence and impact within the United States' healthcare landscape.
TG Therapeutics Inc represents a strong commitment to improving the lives of patients by developing innovative therapies in the field of hematological malignancies and autoimmune diseases. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and collaborative partnerships. With a focus on research and development, TG Therapeutics Inc aims to bring transformative treatments to market that address unmet medical needs. Through its dedication to advancing medical science, this company strives to make a positive impact on the lives of patients, healthcare professionals, and the wider community.
Analyytikot asettavat tällä hetkellä TG Therapeutics-osakkeelle keskimääräisen tavoitehinnan 80,50 USD (mediaani: 80,50 USD), mikä merkitsee +32,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 14 analyytikkoarvioon.
14 analyytikkoa arvioi tällä hetkellä TG Therapeutics-osaketta: 12 suosittaa ostoa, 1 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat TG Therapeutics-yhtiöltä 960,01 M USD liikevaihtoa ja 1,00 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla TG Therapeutics-osake noteerataan hintaan 54,06 EUR (60,75 USD).
TG Therapeutics-osake (TGTX) on listattuna 7 pörssissä, muun muassa: NASDAQ (TGTX), London (0VGI.L), SIX (Zürich) (NKB2.SW), Frankfurt (NKB2.F), München (NKB2.MU), Düsseldorf (NKB2.DU).
TG Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapies for cancer and autoimmune diseases. The company's business model includes the development of new drugs and their marketing. The company is divided into various divisions, each focused on specific therapy areas. These divisions include both cancer therapies and immunotherapies used in autoimmune diseases. Each division is led by highly qualified researchers specialized in researching specific types of cancer and autoimmune diseases and collaborate closely to discover advanced technologies. TG Therapeutics' flagship product is the BTK inhibitor Umbralisib, used in various cancers such as lymphomas or leukemias. This drug is a particularly potent molecule specifically developed for its effect on B lymphocytes. By inhibiting these cells, the division of cancer cells is inhibited, stopping the growth of tumor cells. The medication has great potential in treating cancer patients who do not respond to other therapies. In the field of immunotherapy, the company is developing products such as Ublituximab, used in the treatment of autoimmune diseases such as multiple sclerosis. This drug inhibits the activation of B cells, reducing excessive immune reactions in patients. This leads to a decrease in the number of relapses or symptoms of autoimmune diseases and slows down the progression of the disease. TG Therapeutics follows a business-to-business model, forming partnerships with other companies to market its products. However, the company also has extensive sales and marketing capabilities to sell its products directly to hospitals and medical facilities. There is a particular focus on multiple markets, especially in the USA, Europe, and Asia. The company generates revenue through product sales and partnerships with other biotech companies. These partnerships include research agreements and licensing agreements, where the company licenses its technologies and products to other firms for fees. Thus, TG Therapeutics generates income from various revenue streams and is able to continue its research and development and expand its business. In summary, TG Therapeutics' business model is focused on the development of innovative therapies for cancer and autoimmune diseases. Through the close collaboration between researchers and developers, the company has developed a range of therapies that can be used to treat various diseases. The company aims to market its products globally to maximize its success and increase its value for patients and investors.
odotettu liikevaihto TG Therapeutics on 960,01 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto TG Therapeutics on 158,69 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
TG Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä 61,01. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan TG Therapeutics-osakkeen arvostusta.
TG Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 10,08. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii TG Therapeutics-osakkeen arvostuskennuslukuna.
TG Therapeutics:n Eulpool-laatuscore on 7/10.
TG Therapeutics:n ISIN on US88322Q1085. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
TG Therapeutics:n WKN on A1JXW7. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
TG Therapeutics:n ticker on TGTX. Tämä pörssinoteeraus käytetään TG Therapeutics-osakkeiden kauppaan pörssissä.
TG Therapeutics osake
TG Therapeutics vertaisryhmä
TG Therapeutics Ticker
TG Therapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi TG Therapeutics:sta
Meidän osakeanalyysimme TG Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut TG Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: